Genentech, Inc. is an American biotechnology corporation dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. It is a proud member of the Roche Group, making medicines to treat patients with serious medical conditions.

Genentech, Inc.

TianJin Medical University Eye Hospital is involved in conducting clinical trials and providing information related to eye health and medical studies, self-described as a better way to connect patients with study teams.

TianJin Medical University Eye Hospital

Sierra Oncology is a focused biopharma company that aims to impact global health by addressing high burden diseases through scientific research and innovation, particularly in infectious diseases, HIV, immunology/respiratory, and oncology.

Sierra Oncology

Roche

About Genentech

We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal.

Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. 

Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683)
Monday-Friday, 6am-5pm PST or patientinfo@gene.com. 

Community Guidelines:

1. We want to foster positive conversation and diverse community around the issues we are passionate about. 
To that end, we remove profanity, content that contains credible threats or hate speech, content that is aimed at private individuals, personal information meant to harass someone, and repeated unwanted messages.

2. Don’t mention any medicines by name — ours or anyone else’s.
Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments.

3. This isn’t the place to report or discuss side effects.
This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch.

4. Don’t pitch your product or service.
Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.

Cellective Therapeutics

Tercica

23andMe

Adaptimmune

Constellation Pharmaceuticals

Curis

GlobeImmune

HistoRx

Kleiner Perkins

Mayfield Fund

Genentech

Our #podcast Two Scientists Walk Into a Bar will be returning with a new season soon! We’re looking forward to diving into exciting topics like the intersection of computation and experimentation, exploring new drug delivery methods, and more. Pull up a stool, grab a drink, and get ready to listen in on all things science with our hosts Maria Wilson and Danielle Mandikian. Revisit last season, and learn how to subscribe to catch the latest episodes! http://spr.ly/6044VnQcm

Exciting news for children and adults living with food allergies - the FDA has approved our medicine to reduce allergic reactions in people with one or more food allergies. Read more: http://spr.ly/6045nDMdD

Black patients account for just 5% of clinical trial participants in the U.S., despite making up 13% of the population. This underrepresentation in clinical research is reflective of the deep-rooted history of systemic inequities in healthcare that continue to have generational impacts. Through our Advancing Inclusive Research (AIR) Site Alliance, we’re working to increase diverse representation in our clinical trials to ensure that scientific breakthroughs can benefit all patients. Hear more from our Site Alliance partners in the video below about why this work matters, and learn more here: http://spr.ly/6045VQtWF #BlackHistoryMonth

Amel Lamrad, our Vice President and Head of Business Operations and Communications of Research and Early Development (gRED), is always looking for ways to advance our mission of developing promising therapeutic solutions for patients. Rooted in her personal experience supporting a loved one with cancer, Amel translated her desire to make a difference into action and joined our company as a project coordinator 20 years ago. Since then, Amel has garnered a reputation for her proficiency in defining shared goals across diverse teams, building consensus, and successfully implementing strategic plans. Read about Amel's path toward becoming the leader and mentor she is today: http://spr.ly/6049VVXfT


Twenty years ago, Amel Lamrad came to our company with one goal in mind, to make a positive impact on society. Now serving as the Vice President and Head of Business Operations and Communications for our Research and Early Development organization (gRED), Amel makes a positive impact each day by ensuring teams have the right systems in place to drive groundbreaking research forward. Amel also plays an important role in recruiting, training, and mentoring future leaders in gRED, even dedicating her time to other groups like our Women in Science and Engineering group to connect senior scientists and earlier-career scientists. Learn more about Amel's journey and how she has pushed herself to become a beloved and people-oriented leader. http://spr.ly/6044VVZZ6 


Metric
Company Name	Genentech, Inc.	TianJin Medical University Eye Hospital	Sierra Oncology
Symbol
MSH ID	COM:GENE	COM:PATIENTWING:APP	COM:SIERRAONCOLOGY
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Medical & Healthcare	Pharmaceuticals
Country	US	CN	GB
Stage
Employee Count	20.35K
Website	gene.com	app.patientwing.com/organization	sierraoncology.com
LinkedIn	genentech
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	16.17
28-Day Growth Score	21.25
90-Day Growth Score	46.89
365-Day Growth Score	42.81

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:GENE

Genentech, Inc.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue